Using buprenorphine for outpatient opioid detoxification

Journal of the American Osteopathic Association

Volumn 107, Issue 9 SUPPL. 5, 2007, Pages

  Manlandro, James J ^a  

^a not available   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BUPRENORPHINE; NARCOTIC ANTAGONIST;

HUMAN; METHODOLOGY; OPIATE ADDICTION; OUTCOME ASSESSMENT; REVIEW; UNITED STATES;

BUPRENORPHINE; HUMANS; NARCOTIC ANTAGONISTS; OPIOID-RELATED DISORDERS; OUTCOME ASSESSMENT (HEALTH CARE); UNITED STATES;

EID: 35748932680     PISSN: 00986151     EISSN: 19451997     Source Type: Journal    
DOI: None     Document Type: Article

References (22)

1. Drug Addiction Treatment Act of 2000. Public Law No. 106-310, Title XXXV-Waiver authority for physicians who dispense or prescribe certain narcotic drugs for maintenance treatment or detoxification treatment, 2000. Available at: http://www.buprenorphine.samhsa.gov/fulllaw.html. Accessed June 9, 2004.
2. Clark HW. Office-based practice and opioid-use disorders. N Engl J Med.2003;349:928-930.
3. Office of National Drug Control Policy (ONDCP). Drug Policy Information Clearinghouse. Heroin Fact Sheet June 2003. Available at: http://www.whitehousedrugpolicy.gov/publications/factsht/her oin/197335.pdf. Accessed June 9, 2004.
4. CASA Report. Under the Counter: The Diversion and Abuse of Controlled Prescription Drugs in the U.S. New York, NY: National Center on Addiction and Substance Abuse at Columbia College. Available at http://www.casacolumbia.org /absolutenm/articlefiles/380-under_the_counter_-_diversion.pdf. Accessed September 5, 2007.
5. Substance Abuse and Mental Health Services Administration (SAMHSA). Results From the 2005 National Survey on Drug Use and Health: National Findings. Rockville, Md: Deaprtment of Health and Human Services, SAMHSA, Offie of Applied Studies. NSDUH Series H-30, DHHS Publication SMA 06-4194; 2006. Available at: http://www.oas.sam hsa.gov/NSDUH/2k5NSDUH/2k5results.htm. Accessed September 5, 2007.
6. Sees KL, Delucchi KL, Masson C, Rosen A, Clark HW, Robillard H, et al. Methadone maintenance vs 180-day psychosocially enriched detoxification for treatment of opioid dependence: a randomized controlled trial. JAMA. 2000;283):1303-1310.
7. Johnson RE, Strain EC, Amass L. Buprenorphine: how to use it right. Drug Alcohol Depend. 2003;70(2 suppl):S59-S77
8. Lofwall MR, Stitzer ML, Bigelow GE, Strain EC. Comparative safety and side effect profiles of buprenorphine and methadone in the outpatient treatment of opioid dependence. Addiction Disorders and Their Treatment. 2005;4:49-64.
9. Ewing JA. Detecting alcoholism. The CAGE questionnaire. JAMA. 1984;252:1905-1907.
10. Center for Substance Abuse Treatment. Clinical Guidelines for the Use of Buprenorphine in the Treatment of Opioid Addiction. Treatment Improvement Protocol (TIP) Series 40. DHS Publication No. (SMA) 04-3939. Rockville, Md: Substance Abuse and Mental Health Services Administration; 2004. Available at: http://buprenorphine.sam hsa.gov/Bup%20Guidelines.pdf. Accessed July 31, 2007.
11. American Psychiatric Association. Desk Reference to the Diagnostic Criteria From DSM-IV TR. Washington, DC: American Psychiatric Association; 2000:139-142.
12. Title 42, Part 2 of the Code of Federal Regulations (42CFR, Part 2), 2001. Available at: http://www.access.gpo.gov/nara/cfr/waisidx_01/42cfr 2_01.html. Accessed July 31, 2007.
13. Amass L, Kamien JB, Mikulich SK. Thrice-weekly supervised dosing with the combination buprenorphine-naloxone tablet is preferred to daily supervised dosing by opioid-dependent humans. Drug Alcohol Depend. 2001;61(2):173-181.
14. Casavant MJ. Urine drug screening in adolescents. Pediatr Clin North Am.2002; 49:317-327.
15. Crane E. Narcotic analgesics. The Drug Abuse Warning Network (DAWN) Report. January 2003. Available at: http://oas.samhsa.gov/2k3/pain/DAWNpain. pdf. Accessed September 5, 2007.
16. Fiellin DA, O'Connor PG. Clinical practice. Officebased treatment of opioid-dependent patients. N Engl J Med. 2002;347:817-823.
17. Fudala PJ, Bridge TP, Herbert S, Williford WO, Chiang CN, Jones K, et al for the Buprenorphine/ Naloxone Collaborative Study Group. Officebased treatment of opiate addiction with a sublingual-tablet formulation of buprenorphine and naloxone. N Engl J Med. 2003;349:949-958.
18. Hammett-Stabler CA, Pesce AJ, Cannon DJ. Urine drug screening in the medical setting. Clin Chim Acta. 2002;315(1-2):125-135.
19. McCance-Katz EF, Rainey PM, Friedland G, Kosten TR, Jatlow P. Effect of opioid dependence pharmacotherapies on zidovudine disposition. Am J Addict. 2001;10:296-307.
20. Petitjean S, Stohler R, Deglon JJ, Livoti S, Waldvogel D, Uehlinger C, et al. Double-blind randomized trial of buprenorphine and methadone in opiate dependence. Drug Alcohol Depend. 2001; 62:97-104.
21. Saitz R. Overview of medical and surgical complications of addiction. In: Graham AW, Schultz TK, Mayo-Smith MF, Ries RK, Wilford BB, eds. Principles of Addiction Medicine. 3rd ed. Chevy Chase, Md: American Society of Addiction Medicine; 2003.
22. Strain EC, Walsh SL, Bigelow GE. Blockade of hydromorphone effects by buprenorphine/naloxone and buprenorphine. Psychopharmacology (Berl). 2002;59:161-166.